



A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701-3271 WWW.FULBRIGHT.COM

shighlander@fulbright.com Partner

DIRECT DIAL: (512) 536-3184

TELEPHONE: FACSIMILE:

(512) 474-5201

(512) 536-4598

October 28, 2002

RECEIVED

NOV 0 8 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 2023 of the date below:

October 28, 2002 Date

Steven L. Highlander

Commissioner for Patents Washington, DC 20231

Re: U.S. Serial No. 09/908,988 Entitled: "METHODS AND COMPOSITIONS FOR

STABILIZING MICROTUBULES AND INTERMEDIATE FILAMENTS IN

STRIATED MUSCLE CELLS" by Eric N. Olson

Matter No. 10106332/MYOG:028US

Enclosed for filing in the above-referenced patent application is:

- 1. Response to Restriction Requirement Dated August 29, 2002;
- 2. Request for Extension of Time to Respond to Office Action Dated August 29, 2002; and
- 3. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

COMMISSIONER FOR PATENTS October 28, 2002

Page 2

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10106332/SLH.

ery truly yours,

Steven L. Highlander

SLH/cpj

Encl: As noted





CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, DC 20231, on the date below:

October 28, 2002 Date

Steven L. Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eric N. Olson

Jeffrey A. Spencer

Serial No.: 09/908,988

Filed: July 18, 2001

For: METHODS AND COMPOSITIONS FOR

STABILIZING MICROTUBULES AND INTERMEDIATE FILAMENTS IN

STRIATED MUSCLE CELLS

Group Art Unit: 1632

Examiner: William W. Moore

Atty. Dkt. No.: MYOG:028US

RECEIVED

NOV 0 8 2002

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT DATED AUGUST 29, 2002

Commissioner for Patents Washington, D.C. 20231

Commissioner:

This paper is submitted in response to the Restriction Requirement dated August 29, 2002 for which the date for response was September 29, 2002.

A request for a one-month extension of time to respond is included herewith along with the required fee. This one-month extension will bring the due date to October 29, 2002, which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10106332/SLH.

11/07/2002 DABROWS1 00000091 09908988

01 FC:2252. 25225233.1

55,00 00

In response to the restriction requirement which the Examiner imposed, The examiner has restricted the current invention to one of 45 classes of claims. Applicants traverse this restriction by provisionally electing to purse Group I, claims 1-6 and 8-18, drawn to MURF-1, *i.e.*, the Group I claims.

The examiner has not provided an explanation for why group VII cannot be elected with Group I, therefore applicants act to rejoin these two groups and requests that Examiner allow prosecution of Groups I and VII directed towards MURF-1.

The applicants further act to rejoin Group IV directed to MURF-1. The examiner has argued that Group IV is unrelated to Group I and Group VII because the different inventions are • not disclosed as capable to use together and have different modes of operation, functions, and effects (MPEP 806.04). Group IV, which is limited to Claim 7 alone, is drawn to an expression construct for an anti-sense nucleic acid encoded by the DNA segment of Claim 5. While it is true that an anti-sense construct will have a different final product than its sense counterparts, it is also true that such an expression construct will "define the same essential characteristics" (MPEP 806.03) as the expression construct for the sense molecules, it will be used in the same manner, it is capable of being used with the sense constructs and it will require no more additional burden on the examiner in searching the art because the DNA sequence used for the anti-sense construct is the same as used in the sense constructs. Furthermore, Applicants direct Examiner to the discussion in the specification on pages 29 and 30 displaying not only potential use of anti-sense technology but how it can be used in conjection with other DNA and RNA of the invention to aid in generating further constructs for the invention, a mode clearly contemplated by the inventors and seemingly practicable with the other previously elected groups of claims. Lastly, Applicants refer Examiner to MPEP 808.02 which requires that for restriction, Examiner must show by appropriate explanation one of the following: (1) there is a separation classification of the species; (2) there is a separate status in the art when the subjects are classified together; or (3) there is a different field of search for the subjects. Applicants contend that none of these three requirements is met for the requested grouping and therefore request that Group IV be prosecuted with Groups I and VII.

The Examiner is invited to contact the undersigned attorneyat (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

Steven L Highlander

Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 536-3184

Date:

October 28, 2002